文献速递产科母胎医学

低分子肝素预防子痫前期及胎盘介导并发症的系统综述与荟萃分析

Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-20

该系统综述与荟萃分析纳入15项随机对照试验共2795名高危孕妇,评估低分子肝素(单用或联合低剂量阿司匹林)预防子痫前期及胎盘相关并发症的效果。结果显示低分子肝素可显著降低子痫前期、小于胎龄儿和围产期死亡风险,且孕16周前开始治疗时子痫前期风险降低更明显;与单用低剂量阿司匹林相比,联合治疗可进一步降低子痫前期风险,但证据质量低至中等,存在异质性,需大型试验验证。

要点

  • 高危孕妇使用低分子肝素可降低子痫前期、小于胎龄儿和围产期死亡风险。
  • 孕16周前开始低分子肝素治疗,子痫前期风险降低更显著。
  • 低分子肝素联合低剂量阿司匹林较单用阿司匹林进一步降低子痫前期风险。

核心结论

  • 高危孕妇使用低分子肝素与子痫前期及其他胎盘介导并发症风险显著降低相关。
  • 孕16周前开始治疗时子痫前期风险降低更明显。
  • 低分子肝素联合低剂量阿司匹林较单用低剂量阿司匹林显著降低子痫前期风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Cochrane Central Register of Controlled Trials,无发表时间限制。
  • 纳入15项随机对照试验,共2795名高危孕妇(既往子痫前期、宫内生长受限、胎死宫内或流产史,或早孕期筛查高危)。
  • 比较低分子肝素或普通肝素(±低剂量阿司匹林)与对照,主要结局为子痫前期。
  • 采用随机效应模型计算合并比值比(OR)及95%置信区间(CI),证据质量用GRADE评估。

主要发现

  • 低分子肝素组子痫前期风险降低(OR 0.62,95%CI 0.43-0.90,P=.010)。
  • 小于胎龄儿风险降低(OR 0.61,95%CI 0.44-0.85,P=.003)。
  • 围产期死亡风险降低(OR 0.49,95%CI 0.25-0.94,P=.030)。
  • 孕16周前开始治疗(13项研究,2474名参与者)子痫前期风险降低更明显(OR 0.55,95%CI 0.39-0.76,P=.0004)。
  • 6项随机对照试验(920名参与者)中,低分子肝素联合低剂量阿司匹林较单用低剂量阿司匹林子痫前期风险降低(OR 0.62,95%CI 0.41-0.95,P=.030)。

关键数值与推荐

  • 高危定义:既往子痫前期、宫内生长受限、胎死宫内或流产史,或早孕期筛查子痫前期高危。
  • 主要结局为子痫前期;次要结局包括小于胎龄儿、围产期死亡、流产和胎盘早剥。
  • 证据质量范围为极低至中等,主要因缺乏盲法、不精确性和不一致性。

临床怎么用

  • 对于子痫前期高危孕妇,可考虑使用低分子肝素以降低子痫前期及胎盘介导并发症风险。
  • 建议在孕16周前开始低分子肝素治疗以获得更佳预防效果。
  • 低分子肝素联合低剂量阿司匹林可作为高危孕妇的预防策略,但需结合个体情况。

局限性

  • 存在重要的临床和统计学异质性。
  • 证据质量范围为极低至中等,主要因缺乏盲法、不精确性和不一致性。
  • 结果需大型精心设计的临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on the impact of low-molecular-weight heparin, alone or in combination with low-dose aspirin, for the prevention for preeclampsia in high-risk patients is conflicting. OBJECTIVE: We conducted a meta-analysis of studies published to assess the effectiveness of low-molecular-weight heparin for the prevention of preeclampsia and other placenta-related complications in high-risk women. DATA SOURCES: A systematic search was performed to identify relevant studies, using the databases PubMed and Cochrane Central Register of Controlled Trials, without publication time restrictions. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing treatment with low-molecular-weight heparin or unfractionated heparin (with or without low-dose aspirin), in high-risk women, defined as either history of preeclampsia, intrauterine growth restriction, fetal demise, or miscarriage or being at high risk after first-trimester screening of preeclampsia. STUDY APPRAISAL AND SYNTHESIS METHODS: The systematic review was conducted according to the Cochrane Handbook guidelines. The primary outcome was the development of preeclampsia. We performed prespecified subgroup analyses according to combination with low-dose aspirin, low-molecular-weight heparin type, gestational age when treatment was started, and study population (patients with thrombophilia, at high risk of preeclampsia or miscarriage). Secondary outcomes included small for gestational age, perinatal death, miscarriage, and placental abruption. Pooled odds ratios with 95% confidence intervals were calculated using a random-effects model. Quality of evidence was assessed using the grading of recommendations assessment, development, and evaluation methodology. RESULTS: A total of 15 studies (2795 participants) were included. In high-risk women, treatment with low-molecular-weight heparin was associated with a reduction in the development of preeclampsia (odds ratio, 0.62; 95% confidence interval, 0.43-0.90; P=.010); small for gestational age (odds ratio, 0.61; 95% confidence interval, 0.44-0.85; P=.003), and perinatal death (odds ratio, 0.49; 95% confidence interval, 0.25-0.94; P=.030). This reduction was stronger if low-molecular-weight heparin was started before 16 weeks' gestation (13 studies, 2474 participants) for preeclampsia (odds ratio, 0.55; 95% confidence interval, 0.39-0.76; P=.0004). When only studies including low-dose aspirin as an intervention were analyzed (6 randomized controlled trials, 920 participants), a significant reduction was observed in those with combined treatment (low-molecular-weight heparin plus low-dose aspirin) compared with low-dose aspirin alone (odds ratio, 0.62; 95% confidence interval, 0.41-0.95; P=.030). Overall, adverse events were neither serious nor significantly different. Quality of evidence ranged from very low to moderate, mostly because of the lack of blinding, imprecision, and inconsistency. CONCLUSION: Low-molecular-weight heparin use was associated with a significant reduction in the risk of preeclampsia and other placenta-mediated complications in high-risk women and when treatment was started before 16 weeks' gestation. Combined treatment with low-dose aspirin was associated with a significant reduction in the risk of preeclampsia compared with low-dose aspirin alone. However, there exists important clinical and statistical heterogeneity, and therefore, these results merit confirmation in large well-designed clinical trials.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cruz-Lemini M, Vázquez JC, Ullmo J, et al. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021. PMID: 34301348. doi:10.1016/j.ajog.2020.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。